A5060009115- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Viral-associated cancers and disorders
- Gallbladder and Bile Duct Disorders
- TGF-β signaling in diseases
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Oral health in cancer treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Head and Neck Cancer Studies
- Colorectal Cancer Treatments and Studies
- Salivary Gland Disorders and Functions
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Multiple and Secondary Primary Cancers
- Mycobacterium research and diagnosis
- Prostate Cancer Treatment and Research
- Folate and B Vitamins Research
- Endoplasmic Reticulum Stress and Disease
Ono Pharmaceutical (United States)
2022-2024
Massachusetts General Hospital
2020-2023
Harvard University
2020-2023
All India Institute of Medical Sciences
2010-2019
All India Institute of Medical Sciences Raipur
2019
All India Institute of Medical Sciences Bhopal
2019
DR. B.R.A. Institute Rotary Cancer Hospital
2010-2018
Purpose We designed this study to evaluate efficacy of modified gemcitabine and oxaliplatin (mGEMOX) over best supportive care (BSC) or fluorouracil (FU) folinic acid (FA) in unresectable gall bladder cancer (GBC). Patients Methods with GBC were enrolled for single center randomized study. Arm A, BSC; arm B, FU 425 mg/m 2 FA 20 intravenous (IV) bolus weekly 30 weeks (FUFA); C, 900 80 IV infusion on days 1 8 every 3 maximum six cycles. Eighty-one patients randomly assigned, arms A (n = 27), B...
Abstract Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with other etiologies. We evaluated differences in clinicopathological characteristics patients undergoing resection NAFLD/NASH-associated Methods Demographic, features, survival surgically resected were collected. NAFLD activity score (NAS)...
Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a "trap") fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.
4077 Background: Combination of gemcitabine and platinum (cisplatin/ oxalipatin) though standard for advanced/unresectable GBC has not been directly compared. This study was designed to see if OS with mGEMOX is equivalent GemCis. Methods: Single center phase III randomized trial. Primary end point in 2 groups. Main Secondary points were: 1. PFS groups; 2. RR two Considering median 9.5 month (as per our previous study) 11.7month GemCis 108 patients were required each arm have γ ±2 80% power....
5528 Background: Until the recent FDA approval of pembrolizumab in combination with chemotherapy ± bevacizumab, there have been limited treatment options that address underlying biology for pts persistent, recurrent, or metastatic (P/R/M) locally advanced (LA) cervical cancer. Persistent HPV infection is associated 99% cancers and linked to upregulation TGF-β. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed extracellular domain TGF-βRII (a TGF-β “trap”) fused human...
<p>Figure S1. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for (A) Cohort 1A and (B) 1B. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<p>Figure S2. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<p>Figure S2. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>
<div>AbstractPurpose:<p>Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a “trap”) fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.</p>Patients and Methods:<p>In this multicenter, open-label, phase Ib trial (NCT04551950), P/R/M cancer received bintrafusp alfa...
<div>AbstractPurpose:<p>Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain TGFβ receptor II (a “trap”) fused to human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, metastatic (P/R/M) cervical cancer.</p>Patients and Methods:<p>In this multicenter, open-label, phase Ib trial (NCT04551950), P/R/M cancer received bintrafusp alfa...
<p>Figure S3. Patient-level concentration profile of bintrafusp alfa at Day 1 postdose.</p>
<p>Figure S1. Change from baseline in sum of diameters all target lesions per RECIST v1.1 for (A) Cohort 1A and (B) 1B. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial SD, stable disease.</p>